Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- Registration Number
- NCT00103831
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Advanced or metastatic pretreated NSCLC
- Measurable disease
- Adequate hematologic, hepatic and renal functions.
- ECOG Performance Status 0-2
Exclusion Criteria
- Inability to swallow capsules
- Recent significant cardiovascular disease
- Women who are pregnant or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Local Institution
🇨🇦Toronto, Ontario, Canada